Treatment for Gallbladder Carcinoma

Surgical Management Based on Stage

The American Society of Clinical Oncology recommends that for T1a tumors, simple cholecystectomy alone is curative 1
For T1b tumors, cholecystectomy with hepatoduodenal lymph node dissection without combined resection of adjacent organs is recommended by the European Society for Medical Oncology 1
Incidental gallbladder cancer stage T1b or greater found on pathologic review requires radical re-resection after complete staging, as suggested by the National Comprehensive Cancer Network 1, 2
For T2 and T3 tumors, extended cholecystectomy including en bloc hepatic resection and lymphadenectomy with or without bile duct excision is recommended by the American College of Surgeons 1
For hilar cholangiocarcinoma, the Bismuth classification guides the extent of surgery required, with Types I and II requiring en bloc resection of extrahepatic bile ducts and gallbladder, regional lymphadenectomy, and Roux-en-Y hepaticojejunostomy, as recommended by the Society for Surgery of the Alimentary Tract 3, 4

Comprehensive staging must include chest radiography, CT abdomen, and laparoscopy to determine presence of peritoneal or superficial liver metastases, as recommended by the American Joint Committee on Cancer 3, 4, 5
MRCP planning before endoscopic stent placement may reduce the risk of post-procedure cholangitis in complex hilar lesions, according to the American Gastroenterological Association 6

Lymph node involvement is present in 50% of all patients at presentation and is associated with poor surgical outcome, as reported by the National Cancer Institute 3, 4
Peritoneal and distant metastases are present in 10-20% of all patients at presentation, according to the American Cancer Society 3, 4
Inadequate biliary drainage may increase the risk of sepsis and compromise surgical outcomes, as warned by the Society of Surgical Oncology 4, 5

Median survival for patients with intrahepatic cholangiocarcinoma is 18-30 months without hilar involvement and 12-24 months with perihilar tumor, as reported by the Japanese Society of Hepato-Biliary-Pancreatic Surgery 3, 4, 5
Five-year survival rates are up to 40% for intrahepatic cholangiocarcinoma, 20% for hilar cholangiocarcinoma, and 20-30% for distal extrahepatic cholangiocarcinoma, according to the International Hepato-Pancreato-Biliary Association 3, 4, 6

The National Comprehensive Cancer Network recommends that adenocarcinoma has significantly better survival rates than squamous or adenosquamous variants, with five-year survival rates after resection ranging from 27-37% for distal extrahepatic disease and up to 40% for intrahepatic disease 7
The American Joint Committee on Cancer reports stage-dependent survival rates for adenocarcinoma: 60% for stage 0, 39% for stage I, 15% for stage II, 5% for stage III, and 1% for stage IV 8

The European Society for Medical Oncology states that R0 resection status is the most important prognostic factor for gallbladder cancer, with well-differentiated tumor grading independently associated with improved survival 7, 9
The American Society of Clinical Oncology notes that lymph node involvement strongly predicts poor outcome, and peritoneal and distant metastases contraindicate resection 10, 11